Effect of kiwifruit on vitamin C status of people susceptible to respiratory infections

Effect of kiwifruit intervention on vitamin C status of people with recurrent respiratory infections

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12621000769886

Enrollment

Registered

2021-06-21

Start date

2021-11-19

Completion date

2023-06-15

Last updated

2024-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

People with respiratory infections can exhibit depleted vitamin C status due to the increased turnover and requirement for the vitamin during the inflammatory process. We plan to carry out a 'before and after' study in people susceptible to infectious respiratory exacerbations requiring home antibiotic administration to assess their vitamin C status before and after supplementation with vitamin C-rich kiwifruit (assessed at baseline, 2 weeks and 6 weeks). Secondary outcomes will include assessment of blood and urinary markers of inflammation, oxidative stress and white blood cell status. Questionnaires will assess respiratory symptoms, health-related quality of life, subjective mood, and susceptibility to and severity of subsequent upper respiratory tract infections. We hypothesise that supplementation of vitamin C-rich kiwifruit to these people will enhance their vitamin C status and may decrease inflammatory and oxidative stress biomarkers and improve immune cell parameters. Although not powered to detect changes in clinical outcomes, this data will be used to inform future trials.

Interventions

This is a 'before and after' study whereby participants will consume kiwifruit following baseline visit. - the dose administered: 2 SunGold kiwifruit per day - the frequency of administration: once per day - the duration of administration: 6 weeks - the mode of administration: oral Adherence to intervention will be monitored through measuring plasma vitamin C concentrations (by HPLC)

Study design

Allocation

Non-randomised trial

Intervention model

Single group

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Inclusion criteria: adult aged 18 years and over; respiratory symptoms indicating IV antibiotic therapy in the previous year; symptoms occurring at least once per year

Exclusion criteria

Exclusion criteria: not able to give consent, severe coexisting medical conditions (other than bronchiectasis) which would worsen the prognosis (e.g. heart failure, lung cancer, COPD, cystic fibrosis), dysphagia (swallowing difficulties), known kiwifruit allergy, taking vitamin C-containing supplements at greater than recommended dietary intake (RDI).

Outcome results